Beyond Analysis has launched a new sister company Beyond AML which will assist financial institutions to leverage applied intelligence, data analytics and machine learning to optimise their end-to-end ...
Intellia’s CRISPR/Cas9 proprietary process produces multiple, highly efficient sequential edits in T cells that have superior function and minimal translocations, compared to results from standard T ...
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results